Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Tax Provisions (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Tax Provisions for 9 consecutive years, with $870000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Tax Provisions fell 37.14% to $870000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0 million, a 33.33% increase, with the full-year FY2025 number at $4.0 million, up 33.33% from a year prior.
  • Tax Provisions was $870000.0 for Q4 2025 at Ultragenyx Pharmaceutical, roughly flat from $873000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $6.3 million in Q3 2022 to a low of -$3.9 million in Q4 2023.
  • A 5-year average of $587000.0 and a median of $526500.0 in 2022 define the central range for Tax Provisions.
  • Biggest YoY gain for Tax Provisions was 3354.4% in 2022; the steepest drop was 7355.0% in 2022.
  • Ultragenyx Pharmaceutical's Tax Provisions stood at $20000.0 in 2021, then crashed by 7355.0% to -$1.5 million in 2022, then plummeted by 167.2% to -$3.9 million in 2023, then skyrocketed by 135.7% to $1.4 million in 2024, then tumbled by 37.14% to $870000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Tax Provisions are $870000.0 (Q4 2025), $873000.0 (Q3 2025), and $947000.0 (Q2 2025).